MT. LAUREL, NJ - March 28, 2025 (NEWMEDIAWIRE) - United Health Products, Inc. (OTCPK: UEEC) today provided an update on the company’s regulatory and capital markets activities.
As previously disclosed, the FDA requested that certain additional sterilization and biotoxicity tests be included in the company’s Investigational Device Exemption (IDE) application. An IDE approval is a precondition to commencing the enrollment of 27 patients in UHP’s supplemental clinical study. The company has received the results of these tests which confirm that the sterility and biocompatibility of its CelluSTAT Hemostatic Gause meet the applicable product safety requirements for a Class III, absorbable medical device. UHP has submitted these results to the FDA as part of its revised IDE application.
Separately, in response to UHP’s application for an uplisting of its common shares to be quoted on the OTCQB market, OTC Markets requested certain additional information from the company. This information has now been made available, allowing OTC Markets to complete its review of the application.
There can be no assurance that the FDA Premarket Approval or the OTCQB uplisting applications will be granted.
About United Health Products -- UHP has developed and patented a Neutralized Regenerated Cellulose hemostatic agent. CelluSTAT Hemostatic Gauze is an all-natural product designed to control mild to moderate bleeding. UHP is seeking approval to access the human surgical market.
For more information on UHP visit the company’s new website: www.uhpcorp.com or contact the company at info@uhpcorp.com.
The company can also be reached by phone or text message at 475.755.1005.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.
View the original release on www.newmediawire.com
